U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Clinical Outcome Assessment (COA) Qualification Program
  1. Drug Development Tool (DDT) Qualification Programs

Clinical Outcome Assessment (COA) Qualification Program

The CDER Clinical Outcome Assessment (COA) Qualification Program:

  • Manages the qualification process for COAs intended to address unmet public health needs.
  • Works directly with requestors in guiding COA development for qualification.
  • Encourages a collaborative, multidisciplinary setting where CDER can review COAs and provide advice on the development or modification of COAs outside the IND/NDA/BLA pathway.

COA Qualification:

COA qualification is a regulatory conclusion that the COA is a well-defined and reliable assessment of a specified concept of interest for use in adequate and well-controlled (A&WC) studies in a specified context of use. COA qualification represents a conclusion that within the stated context of use, results of assessment can be relied upon to measure a specific concept and have a specific interpretation and application in drug development and regulatory decision-making.

If you have questions about the CDER COA Qualification Program, please email: COADDTQualification@fda.hhs.gov

Resources for You